ClinicalTrials.gg
CompletedNCT00433329COMPASS 3Updated Feb 4, 2025Results posted

Combination Therapy in Pulmonary Arterial Hypertension

A Phase 4 interventional study of Bosentan and Sildenafil in Pulmonary Arterial Hypertension, sponsored by Actelion. Completed. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-02-04.

Sponsored by Actelion (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing bosentan in Pulmonary Arterial Hypertension — none open to participants now, none under way, none of them phase 3. Bosentan · Pulmonary Arterial Hypertension.

Enrollment
3rd of 18
100 · median 37
Started
2007
with 1 other
Phase 4
5 of 18
none open now
Registered
8th of 18
by date
Lead sponsor
10 of 18
Actelion

Among the 18 studies testing bosentan in Pulmonary Arterial Hypertension, this one is the 3rd largest by enrollment, is one of 2 that started in 2007, is one of 5 in phase 4, and was the 8th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

None of the 18 studies testing bosentan in Pulmonary Arterial Hypertension is open now. The open studies under Pulmonary Arterial Hypertension, anywhere →

About bosentan

Bosentan: first FDA approval 2001 (TRACLEER), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing bosentan in Pulmonary Arterial Hypertension as a file.
02

Study summary

An open label, non-comparative study design is appropriate for this Phase 4 study designed to assess whether a core therapy of bosentan, either as monotherapy or with the addition of sildenafil, enables patients with pulmonary arterial hypertension (PAH) to achieve a 6-minute walk distance (6 MWD) of ≥380 meters after 28 weeks of therapy This design is also appropriate to pioneer the utility of cardiac MRI in assessing improved functional capacity in PAH and exploring its correlation with other parameters.

03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • pulmonary arterial hypertension
  • bosentan
  • sildenafil
  • combination therapy
  • Compass 3
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed prior to initiation of any study-mandated procedures.
  2. Males or females ≥ 12 years of age (females of must have been surgically sterilized or use a reliable method of ).
  3. Symptomatic patients with the following types of PAH belonging to World Health Organization (WHO) Pulmonary Hypertension Classification Group I:

    • Idiopathic (IPAH)
    • Familial (FPAH)
    • Associated with PAH (APAH):

      • Collagen vascular disease
      • Drugs and toxins
  4. Patients naïve to treatment with advanced PAH therapies (i.e., endothelin receptor antagonists (ERAs), phosphodiesterase-5 (PDE-5) inhibitors or prostacyclins) with a right heart catheterization (RHC) showing all of the following:

    • Mean pulmonary arterial pressure (mPAP) ≥ 25 mm Hg
    • Pulmonary capillary wedge pressure (PCWP) ≤ 15 mm Hg or left ventricular end diastolic pressure (LVEDP) ≤ 15 mm Hg when PCWP is not accurately obtained
    • Pulmonary vascular resistance ≥ 3 Wood units
  5. 6-MWT distance ≥ 150 meters and \< 360 meters.

Exclusion criteria

Exclusion Criteria:

  1. Patients with Pulmonary Hypertension (PH) belonging to WHO Classification Group II-V.
  2. Patients with PAH (WHO PH Classification Group I) other than that listed in the Inclusion Criteria.
  3. Pregnant and/or nursing.
  4. Women of not using a reliable method of .
  5. Patients with known (HIV) infection.
  6. Patients with significant vasoreactivity during right heart catheterization (i.e., a fall in mPAP to \< 40 mm Hg with a decrease of ≥ 10 mm Hg and with a normal cardiac index ≥ 2.5 l/min.m\^2).
  7. Patients with restrictive lung disease (i.e., total lung capacity (TLC) \< 60% of normal predicted value).
  8. Patients with obstructive lung disease (i.e., forced expiratory volume/ forced vital capacity (/FVC) \< 0.5).
  9. Patients with impaired left ventricular function ( \<50%) or diastolic dysfunction.
  10. Patients with portal hypertension, cirrhosis, moderate to severe liver impairment ( Class B or C), or liver enzymes ( (AST) and/or alanine aminotransferase (ALT)) > 3.0 times the .
  11. Treatment with glibenclamide (glyburide) and calcineurin inhibitors (cyclosporine A, tacrolimus) sirolimus, everolimus up to 1 week prior to Baseline (Day 1).
  12. Patients currently receiving or predicted to require treatment, during the course of the study, with nitrates, protease inhibitors, or alpha-blockers.
  13. Patients with a concentration \< 75 % of the lower limit of the normal range or \< 8.5 g/dL.
  14. Patients currently receiving or predicted to require treatment with a prostanoid during the course of the study.
  15. Patients with systolic blood pressure \< 85 mm Hg.
  16. Patients with body weight \< 40 kg.
  17. Patients who have received any product within 90 days prior to Baseline.
  18. Patients who previously received any advanced therapy for PAH (e.g., ERAs, PDE-5 inhibitors or prostacyclins).
  19. Patients with to sildenafil or any of its formulation.
  20. Patients with any to sildenafil treatment (i.e., nitrates).
  21. Patients with any recent medical condition limiting the ability to comply with the study requirements (i.e., stroke, myocardial infarction).
  22. Patients with unstable PAH whose disease state would prohibit the completion of study procedures, in the opinion of the investigator.
  23. Patients unable to complete a MRI scan (e.g., claustrophobia).
  24. Patients with permanent cardiac pacemakers, automatic internal cardioverter defibrillators (AICD's), neurostimulators, hearing aides, and other implanted metallic devices that are contraindicated during a MRI study.
  25. Patients with conditions that would interfere with proper cardiac gating during MRI, such as atrial fibrillation or multiple premature ventricular contractions (PVCs)/premature atrial contractions (PACs).
  26. Patients with conditions that prevent compliance with the protocol or the ability to adhere to therapy.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Bosentan

    Oral bosentan 62.5 mg twice daily (BID) first 4 weeks, followed by 24 weeks of 125 mg BID if the 62.5 mg BID dose was well tolerated, with the addition of sildenafil 20 mg thrice daily (TID) in patients who do not reach the 6-MWT distance threshold at Week 16

    Drug: Bosentan · Drug: Sildenafil

Interventions

  • Oral bosentan 62.5 mg BID first 4 weeks followed by 24 weeks of 125 mg BID if the 62.5 mg BID dose was well tolerated

  • Oral sildenafil 20 mg TID in patients who do not reach the 6-MWT distance threshold at Week 16

06

What researchers measure

Primary outcomes

  1. Number of Patients Reaching a 6-Minute Walk Test (6MWT) Distance ≥ 380 Meters

    The 6MWT is a non encouraged test, which measures the walking distance covered over a 6 minute period

    Time frame: at 16 weeks and at 28 weeks of a stepped approach to therapy

07

Results

Posted May 17, 2013

Participant flow

The study was conducted at 23 centers in the United States. First patient, first visit: 25 April 2007; last patient, last visit: 23 April 2010

Participant flow — Overall Study
MilestoneBosentan/Sildenafil
Started100
Completed79
Not completed21
Withdrew: Adverse event9
Withdrew: Death4
Withdrew: Withdrew consent3
Withdrew: Discontinued sildenafil2
Withdrew: Moved out of state1
Withdrew: Lost to follow-up1
Withdrew: Physician decision1

Outcome measures

PrimaryNumber of Patients Reaching a 6-Minute Walk Test (6MWT) Distance ≥ 380 Meters

The 6MWT is a non encouraged test, which measures the walking distance covered over a 6 minute period

Time frame:
at 16 weeks and at 28 weeks of a stepped approach to therapy
Reported as:
Number · participants
Number of Patients Reaching a 6-Minute Walk Test (6MWT) Distance ≥ 380 Meters
participantsBosentan/Sildenafil
Week 1616 (9.4 to 24.7)
Week 2824 (17.5 to 36.3)

Adverse events

Collected over Treatment emergent adverse events (TEAEs) were collected up to 24 hours after study drug discontinuation.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bosentan/Sildenafil—30/100 (30%)88/100 (88%)
Most frequent serious events
Showing 10 of 46
Most frequent serious events
EventBosentan/Sildenafil
PneumoniaInfections and infestations4/100
DyspnoeaRespiratory, thoracic and mediastinal disorders4/100
Pulmonary arterial hypertensionRespiratory, thoracic and mediastinal disorders3/100
AnaemiaBlood and lymphatic system disorders2/100
Cardiac failure congestiveCardiac disorders2/100
Chest painGeneral disorders2/100
BronchitisInfections and infestations2/100
SyncopeNervous system disorders2/100
Renal failureRenal and urinary disorders2/100
Renal failure acuteRenal and urinary disorders2/100
Most frequent other events
Showing 10 of 16
Most frequent other events
EventBosentan/Sildenafil
Oedema peripheralGeneral disorders20/100
DyspnoeaRespiratory, thoracic and mediastinal disorders15/100
HeadacheNervous system disorders13/100
Liver function test abnormalInvestigations10/100
DizzinessNervous system disorders10/100
AnaemiaBlood and lymphatic system disorders9/100
CoughRespiratory, thoracic and mediastinal disorders8/100
FatigueGeneral disorders7/100
BronchitisInfections and infestations7/100
Upper respiratory tract infectionInfections and infestations7/100

Baseline characteristics

Age, Continuous
Age, Continuous(years)Bosentan/Sildenafil
Mean55.5 ± 15.99
Age, Customized
Age, Customized(participants)Bosentan/Sildenafil
Between 21 and 84 years100
Sex: Female, Male
Sex: Female, Male(Participants)Bosentan/Sildenafil
Female82
Male18
Region of Enrollment
Region of Enrollment(participants)Bosentan/Sildenafil
United States100
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Benza RL, Raina A, Gupta H, Murali S, Burden A, Zastrow MS, Park MH, Simon MA. Bosentan-based, treat-to-target therapy in patients with pulmonary arterial hypertension: results from the COMPASS-3 study. Pulm Circ. 2018 Jan-Mar;8(1):2045893217741480. doi: 10.1177/2045893217741480. Epub 2017 Oct 24. PubMed 29064349 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2007, a primary completion of May 2010 and a completion of Aug 2010. It does not say whether these dates are actual or estimated.

Results were first posted in May 2013, 3 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2007
First posted
Feb 9, 2007
Start
Mar 2007
Primary completionActual
May 2010
CompletionActual
Aug 2010
Results first posted
May 17, 2013
Last update
Feb 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00433329
Lead sponsor
Actelion
Responsible party
Sponsor
First posted
Feb 9, 2007
Start date
Mar 2007
Primary completion
May 2010
Completion
Aug 2010
Results posted
May 17, 2013
Last update
Feb 4, 2025
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bosentan

Start the discussion